Search for Stroke in Neurology

An investigational drug shows promise in a phase IIB study.

In the first published randomized trial of patent foramen ovale closure, recurrent strokes were uncommon and usually unrelated to PFO.

This new oral anticoagulant drug significantly reduced the rate of thromboembolism without increasing the rate of intracranial hemorrhage.

Delayed dementia after stroke is common and appears to reflect mostly vascular pathology.

The prevalence of ischemic stroke hospitalizations among people younger than 45 may have risen in recent years.

Diabetes and prior stroke should not preclude use of IV thrombolysis for stroke.

A multicenter study suggests that the presence of mismatch between diffusion-weighted and fluid-attenuated inversion-recovery images may be a useful surrogate marker for ischemic stroke presentation within the time window for treatment with intravenous thrombolysis.

A substudy of the SPARCL trial indicates that patients with stroke or transient ischemic attack benefit from statin therapy regardless of baseline diabetes.

Implementation of a nursing-based protocol for managing acute stroke complications significantly improved outcomes.

A systematic review and meta-analysis finds that depression increases the risk for stroke.

A prospective, community-based study indicates that even short delays in surgery may expose patients to unnecessary risk.

A retrospective cohort study shows encouraging results from endovascular therapy performed beyond 8 hours in patients with a favorable imaging profile — paving the way for a randomized trial.

Silent brain infarcts noted on MRI after a first ischemic stroke are associated with increased risk for recurrent stroke.

Some support for minimization of treatment cessation comes from a new, retrospective, population-based study.

Imaging and treatment were initiated significantly faster when patients with suspected stroke were brought by emergency medical services rather than by private transport, and prehospital notification enhanced that advantage.

Increasing cerebral perfusion with a catheter-based balloon device was safe and possibly beneficial, but only in particular patient subgroups.

Among Medicare beneficiaries, 30-day mortality rates after ischemic stroke, but not 30-day readmission rates, were somewhat better at certified than at noncertified centers.

A large randomized trial failed to show noninferiority or a safety advantage for terutroban, compared with aspirin.

Despite a low per-kilogram dose, the current 90-mg maximum dose seems effective, according to data from a large, international thrombolysis registry.

Currently available neurothrombectomy devices are associated with high rates of recanalization and relatively low rates of harm, according to a meta-analysis.